GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International, Inc. (FRA:HIY1) » Definitions » Sale Of Investment

Heartware International, (FRA:HIY1) Sale Of Investment : €48.3 Mil (TTM As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Heartware International, Sale Of Investment?

Heartware International,'s sale of investment for the three months ended in Jun. 2016 was €33.8 Mil. It means Heartware International, gained €33.8 Mil from selling investments. Heartware International,'s sale of investment for the trailing twelve months (TTM) ended in Jun. 2016 was €48.3 Mil.

Compared with last quarter (€3.1 Mil in Mar. 2016 ), Heartware International, gained more money from selling investments in Jun. 2016 (€33.8 Mil).


Heartware International, Sale Of Investment Historical Data

The historical data trend for Heartware International,'s Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartware International, Sale Of Investment Chart

Heartware International, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.58 78.90 4.63 16.12 31.59

Heartware International, Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.89 6.68 4.77 3.09 33.76

Heartware International, Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was €48.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heartware International, Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Heartware International,'s Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Heartware International, (FRA:HIY1) Business Description

Traded in Other Exchanges
N/A
Address
Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.

Heartware International, (FRA:HIY1) Headlines

No Headlines